QUÉBEC CITY, March 26, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced poster presentations on two of
its anticancer compounds, perifosine and AEZS-136, at the upcoming
American Association for Cancer Research ("AACR") meeting to be
held March 31 - April 4, 2012, at the
McCormick Place in Chicago.
Sunday, April 1, 2012 /
1pm- 5pm (Central)
| Abstract
#871: |
"Dual inhibition of PI3K
and Erk1/2 shows synergy and efficacy in human tumor cells, either
by using drug combinations or novel dual PI3K/Erk inhibitors",
I. Seipelt, M. Gerlach, L. Blumenstein, G. Mueller, E.
Guenther, J. Engel and M. Teifel |
| Presenter: |
Irene Seipelt, PhD, Director,
Preclinical Development, Aeterna Zentaris |
| Session: |
Experimental and Molecular
Therapeutics 4 |
| Venue: |
Hall F, poster section 32, McCormick
Place, Chicago |
Monday, April 2, 2012 /
1pm- 5pm (Central)
| Abstract
#2877: |
"Perifosine alone and in combination with anti-metabolites
interferes with NF-kB pathway activation in colon cancer cell
lines", B. Aicher, P. Schmidt, J. Engel, E. Guenther and M.
Teifel |
| Presenter: |
Babette Aicher, PhD, Director, Preclinical Development, Aeterna
Zentaris |
| Session: |
Experimental and Molecular Therapeutics 23 |
| Venue: |
Hall F, poster section 34, McCormick Place, Chicago |
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. The Company's innovative
approach of "personalized medicine" means tailoring treatments to a
patient's specific condition and to unmet medical needs. Aeterna
Zentaris' deep pipeline is drawn from its proprietary discovery
unit providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.